Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OL2001
- Development stage
- Preclinical
- Lead developer
- Olgram
- Modality
- Small Molecules
01
Overview
OL2001 is a small molecule new chemical entity (NCE) developed by Olgram using an AI-derived drug discovery platform. It is specifically designed to target "persisters," which are dormant, antibiotic-tolerant bacterial subpopulations that contribute to chronic and recurrent infections. By eradicating these persistent bacteria, OL2001 aims to address difficult-to-treat infections that are often resistant to standard antibiotic therapy, including persistent *Pseudomonas aeruginosa* infections in cystic fibrosis patients and various nosocomial (hospital-acquired) infections. The program is currently in the preclinical stage of development.
- Other names
- NAIAP-Olgram
Beyond the preview
Go deeper on OL2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OL2001.